Sangamo raising $51.6 million to fund zinc finger DNA-binding proteins programme
This article was originally published in Scrip
Executive Summary
Sangamo BioSciences has announced the pricing of its public offering of 6.7 million shares at a price of $7.70 per share, bringing in approximately $51.6 million. The shares were priced at a 7.9% discount to the 7 April closing share price of $8.36. Barclays Capital led the offering, and Sangamo has granted the underwriter an option to purchase an additional 1,005,000 shares.